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Abstract 
ELISA is commonly used for the detection of urinary 8-oxo-7,8-dihydro-2'-
deoxyguanosine (8-oxodG), a marker of whole body oxidative stress. However, the 
method has been criticized for high inter-laboratory variability and poor agreement with 
chromatographic techniques. We performed an inter-laboratory comparison of 8-oxodG 
assessed in 30 urine samples and a urine spiked with four different concentrations of 8-
oxodG by ELISA using standardized experimental conditions, including: sample pre-
treatment with solid-phase extraction (SPE), performing analysis using a commercial kit 
from a single manufacturer and strict temperature control during the assay. We further 
compared the ELISA results with high-performance liquid chromatography-tandem mass 
spectrometry (HPLC-MS/MS) and performed tentative identification of compounds that 
may contribute to the discrepancy between both methods. For all but one participating 
laboratory (Data 1) we observed consistent ELISA results lying mostly within 1 SD of the 
mean 8-oxodG concentration. Mean 8-oxodG levels assessed by ELISA correlated with 
the data obtained by HPLC-MS/MS (R=0.679, p<0.001). The correlation improved when 
Data 1 were excluded from the analysis (R=0.749, p<0.001). In the correlation plot we 
identified three outlying urine samples; one with an ELISA 8-oxodG concentration lower, 
and two with 8-oxodG levels higher, than those measured by HPLC-MS/MS. Omitting 
these samples further improved inter-methodology agreement (R=0.869, p<0.001). In the 
outliers with high 8-oxodG estimates various aromatic and heterocyclic compounds were 
tentatively identified using gas chromatography-mass spectrometry (GC/MS); application 
of authentic standards revealed the presence of saccharides, including D-glucose and D-
galactose as putative interfering substances. In summary, assay standardization improved 
ELISA inter-laboratory agreement, although some variability is still observed. While the 
assay shows reasonable correlation with HPLC-MS/MS, there are still compounds in urine 
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that affect the anti-8-oxodG antibody binding, contributing to overestimation of 8-oxodG by 
ELISA in some samples. Thus, despite significant improvement, ELISA still cannot be 
considered a robust alternative to the chromatographic techniques. 
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Introduction 
Oxidative stress, resulting from the imbalance between levels of antioxidants and 
oxidants in the organism, in favor of the latter, represents a major source of damage to 
macromolecules [1]. Although DNA oxidation causes the formation of a number of oxidized 
products [2], 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) is the most abundant and 
most commonly studied oxidized deoxynucleotide [3]. This compound may be measured in 
blood, saliva, urine or other biological matrices [4]. However, due to the availability of urine 
and high stability of 8-oxodG in this matrix [5], urinary levels of 8-oxodG have become a 
popular biomarker of whole body oxidative stress [6]. Although several methods of 8-
oxodG detection have been developed, they may be generally categorized into 
chromatographic and immunochemical approaches [4,7]. Chromatographic techniques, 
particularly high-performance liquid chromatography-tandem mass spectrometry (HPLC-
MS/MS), are considered the gold standard methods of urinary 8-oxodG detection. 
However, for many laboratories obtaining and running expensive chromatographic 
instrumentation is not feasible. Therefore, antibody-based techniques (mostly competitive 
ELISA) are widely used despite their potential shortcomings stemming from non-specific 
interactions of antibodies with compounds in the urine [3]. 
The complex nature of urine, which consists of many chemicals including inorganic 
salts, urea, various organic compounds and organic ammonium salts [8], is main challenge 
to urinary analyzes of 8-oxodG. These compounds may interfere with analytical 
procedures, particularly with antibody-based methods. To overcome this potential source 
of analytical bias, solid-phase extraction (SPE)-based protocols are sometimes used for 
sample pre-treatment [9–11]. It has been shown that the SPE pre-treament significantly 
improves the quality of ELISA data [9,11]. Over the years, several comparisons of 8-
oxodG levels analyzed by chromatography and ELISA have been made [7,11–20]. The 
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agreement between the methods ranged from no correlation (r=0.14, p=0.95) [15] to 
almost perfect agreement (r=0.98, p<0.001) [17]. However, despite reasonable 
correlations observed in some studies, most of the authors reported several-fold higher 8-
oxodG concentrations estimated by ELISA than those measured by chromatography. 
A recent inter-laboratory and between-technique comparison of urinary 8-oxodG 
analyzes organized by the European Standards Committee on Urinary (DNA) Lesion 
Analysis (ESCULA) revealed that not only there is poor agreement between the data 
obtained by ELISA and chromatography, but also high inter-laboratory variability for those 
study participants that used ELISA [7,20]. The studies concluded that ELISA variability is 
greater than the variability of chromatographic methods and that ELISA cannot be used to 
determine absolute levels of 8-oxodG. Moreover, high inter-laboratory ELISA variability 
currently prevents the method from being used for pool data from multiple labs for 
subsequent analysis. 
In the present study we took advantage of ELISA improvements described previously 
[11,16] to conduct the inter-laboratory comparison of 8-oxodG analysis in 30 urine samples 
and a urine spiked with four concentrations of 8-oxodG. The main aim of our work was to 
verify whether application of a common ELISA protocol would help to decrease the inter-
laboratory variability so that it is comparable with that observed for chromatographic 
techniques. We obtained data from five participating laboratories. All participants used a 
commercial ELISA kit from a single manufacturer and adhered strictly to the common 
protocol that included the pre-treatment of urine using SPE and incubation of the purified 
samples with the primary antibody at 4 °C. We further compared the obtained data with 
HPLC-MS/MS analysis and identified samples for which there was a greater disagreement 
between the methods. In these samples we aimed to identify compounds that might 
contribute to the discrepancy. 
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Materials and Methods 
Samples collection 
Spot urine samples were obtained from 30 non-smoking pregnant women (aged 21-38 
y) in Hospital Ceske Budejovice, Czech Republic. These subjects participated in another 
study focused on the effect of environmental pollution on the health of mothers and their 
newborns. All subjects gave signed informed consent and could cancel their participation 
at anytime. The study was approved by the Ethical Committee of the Institute of 
Experimental Medicine in Prague. 
Urine samples were frozen at -20 °C immediately after collection and stored at -80 °C 
after delivery to the Institute of Experiment Medicine. Before analysis in individual 
laboratories, the samples were thawed and aliquoted. A urine sample obtained from a 
healthy male individual (age 43) was spiked with 8-oxodG to reach the final concentration 
of the compound of 0.25; 0.5; 1.0 and 2.5 ng/mL. The samples were coded; the code was 
not known to persons performing the assay. The samples were then shipped on dry ice to 
the study participants.  
 
Pre-treatment of the samples and ELISA 
Before analysis, the samples were thawed and centrifuged for 10 min at 13,000 g. The 
supernatants were used for further analysis. Solid-phase extraction was performed as 
previously described [10] with modifications introduced in [11]. For SPE, 250 µL of urine 
was diluted to 1 mL with HPLC water. After purification and drying under a stream of 
nitrogen, the samples were reconstituted in 250 µL PBS, prior to addittion to the ELISA 
plate. 
For ELISA, the Highly Sensitive 8-OHdG Check kit (JaICA, Shizuoka, Japan) was 
used. The samples were analyzed in triplicate, 50 µL sample/well, according to the 
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manufacturer’s instructions. The instructions included omitting the outer plate wells and 
incubation of the samples with the primary antibody at 4 °C overnight. The results were 
expressed in ng/mL, but for further analyzes they were normalized per creatinine content 
(nmol 8-oxodG/mmol creatinine). 
 
HPLC-MS/MS analysis 
 
Creatinine assay 
The analysis of creatinine was performed by the Jaffe picric acid method [21] 
individually in each participating laboratory. The inter-laboratory variability was very low; 
coefficient of variation (CV) was around 5%. The samples were analyzed in duplicate; 
creatinine concentrations were expressed in mmol/L. 
 
Profiling organic compounds in selected urine samples using GC/MS and HPLC-MS/MS 
The preparation of samples was identical as for ELISA, with the exception of the 
solvent used to dissolve the SPE eluate (methanol instead of PBS). For the analysis, 1 µL 
of the eluate was used; for the identification of saccharides, 50 µL of the eluate was 
transformed to trimethylsilyl derivatives before the analysis. GC separation was performed 
on a fused silica SLB-5ms capillary column (30 m x 0.20 mm x 0.20 µm; Sigma-Aldrich, St. 
Louis, MO, USA) with helium as the carrier gas. A Saturn 2100T ion trap mass 
spectrometer (Varian, Walnut Creek, CA, USA), which operated in electron ionization and 
full scan mode at an electron ionization energy of 70 eV, was used for the detection of the 
unknown substances in urine samples. Tentative identification of unknown selected 
compounds was performed by comparing of their mass spectra with the spectra of the 
NIST (The National Institute of Standards and Technology) library.  
Commented [1]: Hilmi, please, could you add the details? 
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The same samples (1 µL of the eluate dissolved in methanol) were also analyzed by 
HPLC-MS/MS a TripleQuad 6410 triple quadrupole mass spectrometer (Agilent, Santa 
Clara, CA, USA) equipped with an electrospray ion source (ESI), an Agilent 1200 Binary 
Pump System with an autosampler and a MassHunter software system. The ionization of 
the analytes was performed in the positive ion mode and full scan detection. The 
separation of compounds was achieved on a reverse-phase mode using a Supelcosil LC-
PAH HPLC column (150 mm x 3 mm, 5 μm; Supelco, Bellefonte, PA, USA).  
 
Statistical analysis 
First, inter-laboratory variability of 8-oxodG concentrations determined by ELISA was 
tested using ANOVA; the differences between individual laboratories were analyzed using 
Tukey post-hoc test. Then, mean ELISA 8-oxodG values and SD were calculated and 
compared with 8-oxodG concentrations from the HPLC-MS/MS analysis by paired t-tests. 
Agreement between the participating laboratories and between techniques was assessed 
by Pearson correlations and Bland-Altman plots. All calculations were performed using 
SPSS IBM 20 (Chicago, IL, USA). 
 
Results 
The samples were analyzed in five laboratories (Lab 1-Lab 5) from which six sets of 
ELISA data (Data 1-Data 6) and one set of HPLC-MS/MS results were obtained. In one 
laboratory (Lab 5), the ELISA of the urine samples, but not the samples spiked with 8-
oxodG, was performed by two persons independent of each other thus generating to sets 
of data (Data 5 and Data 6). The laboratory responsible for HPLC-MS/MS also conducted 
ELISA (Lab 4, Data 4). The ELISA results were pooled and analyzed separately for the 
urine sample spiked with 8-oxodG and for unspiked urine. 
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Analysis of 8-oxodG in the urine sample spiked with 8-oxodG 
We first analyzed the ability of ELISA to distinguish between urine samples spiked with 
increasing concentrations of 8-oxodG. The results showed consistent data for all 
participating laboratories with the exception of Lab 1 (Data 1; Fig. 1A, Table 1). This 
laboratory detected higher 8-oxodG levels in all tested samples, the estimated 
concentrations laying outside the SD error bars. This resulted in CV ranging from 23.8% to 
47.2% and significant differences of 8-oxodG concentrations between participants 
detected by ANOVA (p=0.013). Excluding Data 1 from the analyzes significantly 
decreased the inter-laboratory variability, although we still observed some samples (those 
analyzed by Lab 4, Data 4) exceeding the SD interval (Fig. 1B). Also the CV decreased to 
the range of 13.7% - 19.6% and no significant difference was found between the 
laboratories (p=0.675) (Table 1). The mean ELISA values showed the concentration trend 
of 8-oxodG, although it was not detected by all laboratories particularly for samples with 
low 8-oxodG levels. Comparison of ELISA results with HPLC-MS/MS showed that, 
unexpectedly, 8-oxodG concentrations measured by chromatography were about 60% 
higher than those detected by ELISA (Table 1). The difference between the methods was 
statistically significant (p<0.001), although there was a good correlation between both data 
sets (R=0.982, p=0.003 and R=0.990, p=0.001 for ELISA data both including and 
excluding Data 1, respectively; Fig. 2A and 2B). The level of agreement between ELISA 
and HPLC-MS/MS results was assessed using Bland-Altman plots (Fig. 2C and 2D). The 
plots show the mean value of the two measurements plotted against the difference 
between these values. They confirmed lower 8-oxodG estimates by ELISA but otherwise 
reasonable agreement between the methods. The agreement further improved after Data 
1 were excluded from the analysis. 
 
10 
Analysis of 8-oxodG in unspiked urine samples 
We further analyzed the inter-laboratory variability of 8-oxodG levels in selected 30 
urine samples. The results demonstrate mostly consistent data across all samples, 
although we observed some outliers (Fig. 3). The greatest departure from the mean values 
was found for the results obtained by Lab 1, for which 50% samples lay outside the SD 
interval. The outliers were also found among data from other participants, particularly Lab 
4, although the deviation from the mean value was less pronounced. The CV of 8-oxodG 
concentrations calculated for individual samples ranged from 10.6% to 53.8%, with the 
mean CV value of 26.6%. Excluding Data 1 from the analysis significantly decreased the 
variability, resulting in the CV ranging between 8.6% and 29.0% (the mean CV value of 
17.6%). This approach, however, emphasized the outliers among Data 4 and changed the 
rank order (Fig. 4). The ELISA data obtained in individual laboratories correlated mostly 
well, with the R value exceeding 0.8 in all but one case (p<0.001; Table 2). The exception 
was, however, Data 1, for which the R value ranged from 0.337 to 0.752 with one non-
significant result (Table 2). The ELISA results from individual laboratories significantly 
correlated with the HPLC-MS/MS data (R ranging from 0.606 to 0.781, p<0.001), again 
with the exception of Data 1 for which the correlation was poor and non-significant (Table 
2). 
The between-technique comparison identified a significant correlation between the 
mean ELISA and HPLC-MS/MS data (R=0.679, p<0.001; Fig. 5A). Although the correlation 
was significant, we observed three notable outliers: one sample with 8-oxodG 
concentration identified by the ELISA as being lower than that by the chromatography 
(sample 18) and two samples with ELISA 8-oxodG estimates higher than by HPLC-MS/MS 
(samples 20, 21; the three outliers circled in red in Fig. 5B). Excluding Data 1 improved the 
correlation (R=0.749, p<0.001; Fig. 5B), but the outliers were still present. Again, the 
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ELISA underestimated 8-oxodG concentrations, although the disagreement was less 
obvious as can be seen in Bland-Altman plots (Fig. 5B and 5D). The plots also showed the 
three outliers mentioned before. For all of them, the disagreement exceeded the 
confidence limits for bias of 2SD. 
To see how the results would change if the three outliers were not present, we 
calculated correlations and prepared Bland-Altman plot after excluding these samples from 
the analysis. The correlation between the ELISA and the HPLC-MS/MS data further 
improved (R=0.869, p<0.001; Fig. 6A), as did the between-technique agreement. The 
ELISA still underestimated 8-oxodG levels (the difference analyzed by the paired t-test 
being significant, p<0.001), although the interval for confidence limits for bias was 
narrower (Fig. 6B). 
 
Profiling organic compounds in the ELISA outliers 
The discrepancy between the methods observed for the three outlying samples did not 
seem to be primarily driven by non-consistent data generated by the ELISA in individual 
laboratories. Although some samples lay outside the SD interval in the inter-laboratory 
comparison (Fig. 4), the CV was acceptable (12.9; 15.8 and 24.2%, for sample 20, 18 and 
21, respectively) and the ELISA data from all laboratories were consistently higher (for 
samples 20, 21) or lower (for sample 18) than the chromatography results. Thus, we 
assumed that the lack of agreement is method-specific, probably associated with specific 
compounds causing cross-reactivity of the primary antibody used in ELISA. To elucidate 
potential differences in chemical composition of the urine, we performed GC-MS and 
HPLC-MS/MS analyzes of the outlying samples and compared them with the sample for 
which 8-oxodG concentration was comparable using both methods (sample 13, denoted 
further as the control sample). 
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The GC-MS allows detection of volatile non-polar and moderately polar compounds as 
well as their quantification and tentative identification. The chromatograms of the samples 
20 and 21 (higher 8-oxodG concentrations by ELISA) were characterized by a number of 
peaks that were not present in the chromatogram of the control sample 13 (Fig. 7A, 7B, 
7D). On the other hand, the number of peaks in sample 18 was lower than in the control 
sample 13 (Fig. 7C and 7D). Most of the compounds tentatively identified based on the 
chromatograms contained aromatic or heterocyclic rings (Table 3). The sum of their 
concentrations was greatest for sample 21 for which the highest disagreement between 
the methods was observed (2.33-fold difference in 8-oxodG concentration between ELISA 
and HPLC-MS/MS). 
Detection of saccharides by the GC-MS based on the application of authentic 
standards revealed a similar trend with the highest concentration sum observed for  
sample 21. In this sample we identified almost 26-fold higher concentration of beta-D-
galactose and almost 30-fold higher concentration of beta-D-glucose than in the control 
sample 13 (Table 4). 
For profiling the organic compounds not detectable by the GC-MS we used the HPLC-
MS/MS. Although this method did not allow tentative identification of the compounds in the 
eluates, we found different peak profiles in the individual samples. This was particularly 
true for sample 20 and 21 when compared with the control sample 13 In these two 
samples we observed extra peaks not detected in samples 13 and 18 suggesting the 
presence of compounds possibly interfering with 8-oxodG detection by ELISA (Fig. 8). 
 
Discussion 
Due to the relative simplicity, speed and low cost of the laboratory equipment and 
chemicals, ELISA is considered an attractive alternative to the chromatographic methods 
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for detection of 8-oxodG in urine samples. However, there is a concern regarding the 
specificity of the anti-8-oxodG antibodies presently available and thus the agreement 
between the ELISA and chromatography data. Moreover, ELISA seems to be prone to 
higher inter-laboratory variability than chromatography [7,20] which currently disqualifies 
the method from application in large, multicenter studies and/or meta-analyzes. Several 
attempts have been made to improve ELISA-chromatography agreement while analyzing 
urinary 8-oxodG levels. They included HPLC pre-purification of urine before ELISA [13], 
incubation of the primary antibody with the samples at lower temperature (4 °C) [16] and 
application of urease to remove urea that has been shown to cross-react with the primary 
antibody [17]. However, to the best of our knowledge, our study is the first one to address 
the issue of substantial inter-laboratory variability previously observed for ELISA. Also, for 
the first time, the SPE pre-treament together with the standardized protocol was tested on 
a larger sample set with the aim to improve ELISA-chromatography agreement. 
As the clone of anti-8-oxodG antibody and the ELISA format (commercial kit vs. in-
house assay) have been shown to significantly impact the results [7,11], we opted for the 
commercial ELISA kit provided by a single manufacturer (Highly Sensitive 8-OHdG Check 
kit; JaICA, Shizuoka, Japan) to be used by all participating laboratories. Moreover, the 
urine samples were processed and the ELISA performed using a standardized protocol 
that has been shown to give best results when compared with the HPLC-MS/MS [11]. This 
included samples pre-purification by SPE previously advocated for HPLC-MS/MS 
application [10] and incubation of the samples with the primary antibody at 4 °C overnight, 
an approach tested by Evans et al. [16] and now recommended by the kit manufacturer. 
The results were corrected to creatinine levels as we have shown that creatinine cross-
reacts with the anti-8-oxodG antibody and creatinine normalization improves between-
technique correlation [11]. One of the participating laboratories further analyzed 8-oxodG 
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levels by HPLC-MS/MS. The data were then tested for inter-laboratory agreement and the 
mean ELISA 8-oxodG levels were compared with the HPLC-MS/MS data to check for 
between-technique variability. 
Even though the standardized ELISA protocol was used, one of the participating 
laboratories delivered results that in many cases were not in agreement with other ELISA 
data and that exhibited poor correlation with both other ELISA results and HPLC-MS/MS 
data. Despite our efforts we were not able to identify the source of disagreement for these 
data. To exclude the impact of potential (although not proven) experimental issues, we 
presented our data both with and without the outlying ELISA results. Excluding these 
results helped to improve both inter-laboratory and between-technique correlation and 
agreement, particularly for the urine sample spiked with different 8-oxodG concentrations. 
For this sample we observed concentration-dependent increase of 8-oxodG and good 
correlation and agreement with the HPLC-MS/MS data, although the chromatography 
detected lower 8-oxodG levels than the ELISA. This result was unexpected as most of the 
previous studies comparing these techniques proved that the ELISA overestimated 8-
oxodG concentrations, probably due to the non-specific interaction of the primary antibody 
with the urine compounds [7,12–15,17–22]. However, in another study, the ELISA 
underestimated 8-oxodG levels after incubation of the samples with the primary antibody 
at 4 °C, although this difference was not statistically significant [16]. 
Excluding the outlying Data 1 from the analysis of unspiked urine samples improved 
inter-laboratory variability, although we still observed the samples exceeding the SD 
interval. Overall, the correlation between the ELISA data from individual laboratories was 
statistically significant with correlation coefficient mostly above 0.8. The correlation 
between ELISA and HPLC-MS/MS was also significant, but correlation coefficients were 
lower. In the correlation and Bland-Altman plots we detected three notable outliers which 
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significantly contributed to the discrepancy between both sets of data. Omitting them 
further improved the data agreement bringing the correlation coefficient to R=0.869 and 
narrowing confidence limits for bias in Bland-Altman plot. While two of these outliers 
exhibited higher 8-oxodG estimates by the ELISA, the third sample had more than 40% 
higher 8-oxodG concentration detected by the HPLC-MS/MS. 
As the three outliers were clearly the samples causing most of the between-technique 
disagreement (after omitting Data 1), we attempted to characterize the profile of organic 
compounds by GC-MS and HPLC-MS/MS. This combined approach allowed us to detect 
compounds with various chemical properties, taking advantage of public databases to 
tentatively identify GC-MS detected peaks and authentic standards to identify selected 
mono- and disaccharides. The two samples with higher ELISA 8-oxodG estimates 
exhibited a number of compounds either not present in the control sample 13, or present 
at very low concentrations. This suggests that 8-oxodG overestimation is caused by the 
cross-reactivity of the antibody with these (and possibly other) compounds that remained 
in the urine despite the SPE pre-treatment. Although the identification is tentative, we can 
broadly classify them as aromatic and heterocyclic compounds, e.g. compounds 
containing structures similar to 8-oxoguanine in 8-oxodG. Furthermore, authentic 
standards allowed identification of several monosaccharides, from which concentrations of 
beta-D-galactose and alpha- and beta-D-glucose in two ELISA outliers (samples 20 and 
21) several fold exceeded those in the control sample 13. The structures of these 
compounds are partially similar to 2'-deoxy-D-ribose in 8-oxodG. Moreover, it has been 
reported that the epitope of the primary antibody spans from the hydroxyl group on C8 of 
guanine to the 2'-deoxyribose backbone [23], making the cross-reactivity of the antibody 
with the above-mentioned monosaccharides likely. It should be mentioned that although 
the concentrations of these monosaccharides were relatively high compared to the control 
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sample 13, they were within a lower interval of the physiological range for healthy subjects 
reported in the literature [24]. This implies that provided that the two monosaccharides 
contribute to the cross-reactivity of the primary antibody, urine samples from any person 
may yield false-positive 8-oxodG concentrations. However, we should point out that our 
experiments did not conclusively prove the cross-reactivity of the primary antibody with the 
compounds detected in the chromatograms. To do that, we would have to use the 
compounds suspected from the cross-reactivity as competitors in the ELISA and check the 
levels of antibody binding inhibition. This was, however, out of the scope of our present 
study but points to the direction of future work. Some such tests have been done 
previously for several nucleosides, urea, creatine and creatinine with no cross-reactivity 
detected [23], although later studies found cross-reactivity with urea [17] and creatinine 
[11]. While the effect of these compounds can be eliminated by SPE or normalization per 
creatinine levels, there are probably many other urine components that affect the ELISA 8-
oxodG assessment and the effect of which cannot be removed by the above-mentioned 
approaches. 
The third outlier contained lower 8-oxodG concentration than the control sample 13. 
This result is difficult to explain by the simple cross-reactivity of the primary antibody with 
urine components. Evans et al. speculated that other high molecular weight compounds in 
urine, dissimilar to 8-oxodG (proteins, saccharides), may also contribute to ELISA vs. 
HPLC-MS/MS disagreement [16]. As the 8-oxodG ELISA has a competitive format, we 
suggest that such compounds could possibly physically block the binding of the primary 
antibody to the antigen in the sample thus facilitating the interaction of the antibody with 
the antigen immobilized to the bottom of the wells thus decreasing the estimate of 8-
oxodG in the urine. However, if true, these compounds are hypothetical as they were not 
detected in any of the chromatograms. 
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The data presented in our manuscript indicate that: (1) Inter-laboratory comparison of 
the ELISA results is possible, although with some reservations. The fact that we were not 
able to identify the reason for discrepancy observed particularly for Data 1 is worrying and 
suggests that under certain circumstances the method may not generate reproducible 
results. For inter-laboratory analyzes this may be relatively easily overcome by 
administration of a urine sample to all study participants that would serve as a common 
standard. Subsequently, the data from the laboratories that showed discrepancies in the 
concentrations of these standards would be excluded. (2) The agreement between 8-
oxodG ELISA and HPLC-MS/MS can be significantly improved by approaches described 
previously, specifically urine pre-treatment by SPE [11] and incubation of the primary 
antibody with the samples at 4 °C [16]. However, even these steps do not guarantee a 
perfect agreement between the techniques, as (yet to be identified) compound(s) in some 
urine samples may interfere with the antibody binding and cause falsely high or low 8-
oxodG estimates. This fact particularly complicates a routine application of ELISA for 8-
oxodG analysis, as currently there is no way to identify the outliers without running HPLC-
MS/MS analysis alongside ELISA. However, this would  eliminate any advantage of ELISA 
as a fast, easy and relatively inexpensive method. 
Although it is a known fact that there exists a discrepancy between ELISA and 
chromatography and the latest study describing the steps that would improve between-
technique agreement was published two years ago [11], new papers still appear that do 
not take the necessary improvement steps into account. Out of 17 human studies 
published between 2013 and 2015 that we found in the PubMed database using keywords 
“8-oxodG” or “8-OHdG” “urine” and “ELISA” and for which we were able to retrieve full-text, 
only one acknowledged improvement of ELISA by the incubation of primary antibody at 4 
°C [25] and none of them used the SPE pre-treatment step. Furthermore, we found two 
Commented [5]: It is true that the kit is standardized and 
the 8-oxodG standards provided with the it could be  used to 
revealed variability between laboratories. However, this 
approach would eliminate urine processing (centrifugation, 
dilution) and SPE where errors may also arise. That's why I 
thought urine samples might be better as common standards. 
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studies that described development of new methods for 8-oxodG detection in urine [26,27]. 
The authors of both studies validated the new methods by comparing the results with 8-
oxodG concentrations measured by ELISA kits rather than by the gold standard 
chromatographic methods. Moreover, the urine samples were not pre-treated, except for 
removal of precipitates by centrifugation and filtration. 
In light of the results of our present study, it should be advisable to always combine the 
8-oxodG ELISA analysis with the SPE pre-treatement keeping in mind that even these 
steps will not guarantee reliable 8-oxodG detection for some samples. 
 
Summary 
In the present study we showed that using a standardized protocol and a commercial 
kit from a single manufacturer led to a good inter-laboratory agreement of 8-oxodG 
analysis by ELISA for most of the participating laboratories. However, to eliminate a 
laboratory/laboratories generating possibly outlying data, common urine standards should 
be distributed along the analyzed samples. 
The modified ELISA reported here substantially improved agreement of the method 
with HPLC-MS/MS analysis. However, we still detected some samples with 8-oxodG 
values that differed from the HPLC-MS/MS data. Because it is impossible to predict such 
samples and thus to exclude them from the analysis, we conclude that currently the ELISA 
is not suitable as a replacement for chromatographic methods. To achieve that, interfering 
substances would have to be identified and pre-purification steps would have to be further 
optimized. 
It is essential for the scientific community to be aware of advantages of the modified 
ELISA and apply the recommended steps that are currently known to improve inter-
laboratory and between-technique agreement. However, at the same time, the limitations 
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of the assay should be considered when planning the experiments to avoid generation of 
misleading data. More work is needed to to further improve the quality of the ELISA data. 
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Figure Legends 
Figure 1. 8-OxodG concentrations in unspiked urine (sample 1) and the urine sample 
spiked with known concentrations of 8-oxodG (sample 2-5) analyzed by ELISA in all 
participating laboratories (Fig. 1A) and in four laboratories after Data 1 have been 
excluded (Fig. 1B). Mean 8-oxodG values (red horizontal sign) and SD (red vertical bars) 
are shown. 
Figure 2. Correlation and between-technique agreement for 8-oxodG concentrations in 
unspiked urine and the urine sample spiked with known concentration of 8-oxodG 
measured by ELISA and HPLC-MS/MS. The ELISA data from all participating laboratories 
correlated well with chromatography (R=0.982, p=0.003; Fig. 2A); the correlation improved 
slightly after Data 1 have been excluded from the analysis (R=0.990, p=0.001; Fig. 2B). 
However, Bland-Altman plot showed underestimation of 8-oxodG levels by ELISA (Fig. 2C, 
2D). The between-technique agreement improved after Data 1 have been removed from 
the analysis (Fig. 2D). 
Figure 3. Ranked mean 8-oxodG concentrations and SD in urine samples analyzed by 
ELISA in all participating laboratories. Mean 8-oxodG values (red horizontal sign) and SD 
(red vertical bars) are shown. 
Figure 4. Ranked mean 8-oxodG concentrations and SD in urine samples analyzed by 
ELISA in the participating laboratories after excluding Data 1. Mean 8-oxodG values (red 
horizontal sign) and SD (red vertical bars) are shown. 
Figure 5. Correlation and between-technique agreement for 8-oxodG levels in urine 
samples analyzed by ELISA and HPLC-MS/MS. There was a significant correlation 
between ELISA data from all participating laboratories and HPLC-MS/MS (R=0.679, 
p<0.001; Fig. 5A), that further improved after Data 1 have been excluded from the analysis 
(R=0.749, p<0.001; Fig. 5B). Bland-Altman plots showed underestimation of 8-oxodG 
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levels by ELISA and improved agreement after removal of Data 1 from the analysis (Fig. 
5C, 5D). There were three notable outliers detected in both correlation and Bland-Altman 
plots (samples 18, 20, 21; circled in red in Fig. 5B). Sample 13 (the control sample): near 
perfect between-technique agreement has been obtained; the sample was used as a 
control in identification of compounds in the outliers (more details in the text and Fig. 7). 
Figure 6. Correlation and between-technique agreement for 8-oxodG levels in urine 
samples analyzed by ELISA and HPLC-MS/MS after the three outlying samples have been 
excluded. The correlation between the data improved (R=0.869, p<0.001; Fig. 6A), 
although the difference between the methods was still statistically significant (p<0.001). 
The ELISA underestimated 8-oxodG levels, although the between-technique agreement 
improved resulting in narrower interval for confidence limits for bias (Fig. 6B). 
Figure 7. GC-MS chromatograms and tentative identification of organic compounds in the 
urine samples for which the ELISA 8-oxodG levels were substantially higher (sample 20, 
Fig. 7A; sample 21, Fig. 7B) and lower (sample 18, Fig. 7C) than those assessed by the 
HPLC-MS/MS. In sample 13 comparable 8-oxodG concentrations were obtained by both 
methods (Fig. 7D). 
Figure 8. HPLC-MS/MS chromatograms of organic compounds in the urine samples for 
which the ELISA 8-oxodG levels were substantially higher (sample 20, Fig. 8A; sample 21, 
Fig. 8B) and lower (sample 18, Fig. 8C) than those assessed by the chromatography. In 
sample 13 comparable 8-oxodG concentrations were obtained by both methods (Fig. 8D).
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Table 1. Creatinine-normalized 8-oxodG levels in unspiked urine and in the urine sample spiked with known concentration of 8-oxodG: 
pooled ELISA data from all participating laboratories; the data after excluding the outlying results; the results obtained by HPLC-MS/MS. 
Sample (ID) 8-oxodG (ELISA, all data) 8-oxodG (ELISA, excl. Data 1) HPLC-MS/MS 
 Mean±SD (nmol/mmol)a CV (%) Mean±SD (nmol/mmol)b CV (%) 8-oxodG (nmol/mmol) 
Urine (1) 1.73±0.49 28.5 1.53±0.21 14.0 2.58 
Urine + 8-oxodG 0.25 ng/mL (2) 2.16±0.85 39.2 1.75±0.24 14.0 3.08 
Urine + 8-oxodG 0.5 ng/mL (3) 2.17±0.73 33.5 1.86±0.26 14.2 3.11 
Urine + 8-oxodG 1 ng/mL (4) 2.76±1.31 47.2 2.19±0.30 13.7 3.47 
Urine + 8-oxodG 2.5 ng/m (5) 3.65±0.87 23.8 3.36±0.66 19.6 4.67 
 
a  p=0.013, results of ANOVA, a comparison of all laboratories running ELISA 
b p=0.675, results of ANOVA, a comparison of laboratories running ELISA after excluding Data 1
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Table 2. Pearson correlation between 8-oxodG levels in 30 urine samples measured by 
ELISA in individual laboratories and by HPLC-MS/MS. 
 
 ELISA 
Data 2 
ELISA 
Data 3 
ELISA 
Data 4 
ELISA 
Data 5 
ELISA 
Data 6 
HPLC-
MS/MS 
ELISA 
Data 1 
R=0.543; 
p=0.002 
R=0.752; 
p<0.001 
R=0.462; 
p=0.013 
R=0.514; 
p=0.004 
R=0.337; 
p=0.068 
R=0.267; 
p=0.153 
ELISA 
Data 2 
 R=0.908; 
p<0.001 
R=0.916; 
p<0.001 
R=0.917; 
p<0.001 
R=0.900; 
p<0.001 
R=0.751; 
p<0.001 
ELISA 
Data 3 
  R=0.888; 
p<0.001 
R=0.845; 
p<0.001 
R=0.730; 
p<0.001 
R=0.606; 
p<0.001 
ELISA 
Data 4 
   R=0.846; 
p<0.001 
R=0.837; 
p<0.001 
R=0.636; 
p<0.001 
ELISA 
Data 5 
    R=0.887; 
p<0.001 
R=0.735; 
p<0.001 
ELISA 
Data 6 
     R=0.781; 
p<0.001 
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Table 3. Tentative identification of abundant compounds in selected urine samples by GC-MS. 
 
 Sample ID (concentration, ng/ml) 
Compound 18 20 21 13 
Benzeneacetic acid, methyl ester 463 24716 30532 1034 
2-Methyl-4-propyl-thiazole 6.2 10031 8852 0 
Azidotrimethylsilane 0 30251 48094 118 
Benzamide 0 560 478 0 
Benzeneacetamide 0 10702 14361 0 
Benzeneacetic acid 0.5 286 386 0.5 
5-Amine_N(Phenylmethyl)-1H-Tetrazole 0 22879 16382 5.3 
3,4-Dibenzyloxyphenol 0 1808 2118 65.8 
1,3-Diphenyl-2-propanone  0.6 2493 2073 45.8 
N-(phenylacetyl)-glycine  0.3 9741 12793 20 
26 
4-OH-2-Propenoic acid 1.5 449 891 1.4 
Pregnane-3,20-diol diacetate (peak 1) 592 1746 2472 1163 
Pregnane-3,20-diol diacetate (peak 2) 22.6 86.8 290 102 
 
 
 
 
 
Table 4. Identification and quantification of saccharides in selected urine samples by GC-MS based on authentic standards. Fold 
difference is related to comparison of saccharide concentrations between samples 18, 20, 21 and the control sample 13. 
 
 Sample ID (concentration, ng/ml) (fold difference) 
Compound 18 20 21 13 
alfa-D-Galactose 4.9 (0.02) 11.9 (0.05) 15.5 (0.06) 239 
D-Mannose 550 (1.48) 745 (2.00) 444 (1.19) 372 
beta-D-Galactose 52.3 (1.29) 75.2 (1.86) 1031 (25.5) 40.5 
27 
alfa-D-Glucose 56.7 (1.31) 119 (2.75) 1276 (29.5) 43.2 
beta-D-Glucose 119 (0.64) 628 (3.36) 1431 (7.67) 187 
alfa-Lactose 162 (0.40) 161 (0.40) 306 (0.76) 404 
Trehalose 6.5 (1.63) 0.0 (0) 0.0 (0) 4.0 
beta-Lactose 112 (0.28) 154 (0.39) 342 (0.86) 396 
 
 
 
 
 
 
 
28 
References 
[1] R.J. Delfino, N. Staimer, N.D. Vaziri, Air pollution and circulating biomarkers of 
oxidative stress, Air Qual Atmos Health, 4 (2011) 37–52. 
[2] M.S. Cooke, M.D. Evans, M. Dizdaroglu, J. Lunec, Oxidative DNA damage: 
mechanisms, mutation, and disease, FASEB J, 17 (2003) 1195–1214. 
[3] M.S. Cooke, R. Olinski, S. Loft, Measurement and meaning of oxidatively modified 
DNA lesions in urine, Cancer Epidemiol Biomark. Prev, 17 (2008) 3–14. 
[4] P. Rossner Jr., R.J. Sram, Immunochemical detection of oxidatively damaged DNA, 
Free Radic Res, 46 (2012) 492–522. 
[5] S. Loft, P. Svoboda, H. Kasai, A. Tjonneland, U. Vogel, P. Moller, K. Overvad, O. 
Raaschou-Nielsen, Prospective study of 8-oxo-7,8-dihydro-2’-deoxyguanosine excretion 
and the risk of lung cancer, Carcinogenesis, 27 (2006) 1245–50. 
[6] M.S. Cooke, A commentary on “Urea, the most abundant component in urine, cross-
reacts with a commercial 8-OH-dG ELISA kit and contributes to overestimation of urinary 
8-OH-dG” What is ELISA detecting?, Free Rad Biol Med, 47 (2009) 30–1. 
[7] L. Barregard, P. Moller, T. Henriksen, V. Mistry, G. Koppen, P. Rossner Jr., R.J. 
Sram, A. Weimann, H.E. Poulsen, R. Nataf, R. Andreoli, P. Manini, T. Marczylo, P. Lam, 
M.D. Evans, H. Kasai, K. Kawai, Y.S. Li, K. Sakai, R. Singh, et al., Human and 
Methodological Sources of Variability in the Measurement of Urinary 8-Oxo-7,8-dihydro-2’-
deoxyguanosine, Antioxid Redox Signal, 18 (2013) 2377–2391. 
[8] C. Rose, A. Parker, B. Jefferson, E. Cartmell, The Characterization of Feces and 
Urine: A Review of the Literature to Inform Advanced Treatment Technology, Crit. Rev. 
Environ. Sci. Technol., 45 (2015) 1827–1879. 
[9] S. Haghdoost, S. Czene, I. Naslund, S. Skog, M. Harms-Ringdahl, Extracellular 8-
oxo-dG as a sensitive parameter for oxidative stress in vivo and in vitro, Free Radic Res, 
39 (2005) 153–62. 
[10] P.M. Lam, V. Mistry, T.H. Marczylo, J.C. Konje, M.D. Evans, M.S. Cooke, Rapid 
measurement of 8-oxo-7,8-dihydro-2’-deoxyguanosine in human biological matrices using 
ultra-high-performance liquid chromatography-tandem mass spectrometry, Free Radic Biol 
Med, 52 (2012) 2057–63. 
[11] P. Rossner Jr., V. Mistry, R. Singh, R.J. Sram, M.S. Cooke, Urinary 8-oxo-7,8-
dihydro-2’-deoxyguanosine values determined by a modified ELISA improves agreement 
with HPLC-MS/MS, Biochem Biophys Res Commun, 440 (2013) 725–730. 
29 
[12] R. Yoshida, Y. Ogawa, H. Kasai, Urinary 8-oxo-7,8-dihydro-2’-deoxyguanosine values 
measured by an ELISA correlated well with measurements by high-performance liquid 
chromatography with electrochemical detection, Cancer Epidemiol Biomark. Prev, 11 
(2002) 1076–1081. 
[13] K. Shimoi, H. Kasai, N. Yokota, S. Toyokuni, N. Kinae, Comparison between high-
performance liquid chromatography and enzyme-linked immunosorbent assay for the 
determination of 8-hydroxy-2’-deoxyguanosine in human urine, Cancer Epidemiol Biomark. 
Prev, 11 (2002) 767–770. 
[14] C.W. Hu, M.T. Wu, M.R. Chao, C.H. Pan, C.J. Wang, J.A. Swenberg, K.Y. Wu, 
Comparison of analyses of urinary 8-hydroxy-2’-deoxyguanosine by isotope-dilution liquid 
chromatography with electrospray tandem mass spectrometry and by enzyme-linked 
immunosorbent assay, Rapid Commun Mass Spectrom, 18 (2004) 505–510. 
[15] M.S. Cooke, R. Singh, G.K. Hall, V. Mistry, T.L. Duarte, P.B. Farmer, M.D. Evans, 
Evaluation of enzyme-linked immunosorbent assay and liquid chromatography-tandem 
mass spectrometry methodology for the analysis of 8-oxo-7,8-dihydro-2’-deoxyguanosine 
in saliva and urine, Free Radic Biol Med, 41 (2006) 1829–1836. 
[16] M.D. Evans, R. Singh, V. Mistry, K. Sandhu, P.B. Farmer, M.S. Cooke, Analysis of 
urinary 8-oxo-7,8-dihydro-purine-2’-deoxyribonucleosides by LC-MS/MS and improved 
ELISA, Free Radic Res, 42 (2008) 831–40. 
[17] M.F. Song, Y.S. Li, Y. Ootsuyama, H. Kasai, K. Kawai, M. Ohta, Y. Eguchi, H. 
Yamato, Y. Matsumoto, R. Yoshida, Y. Ogawa, Urea, the most abundant component in 
urine, cross-reacts with a commercial 8-OH-dG ELISA kit and contributes to 
overestimation of urinary 8-OH-dG, Free Radic Biol Med, 47 (2009) 41–6. 
[18] M.S. Cooke, L. Barregard, V. Mistry, N. Potdar, R. Rozalski, D. Gackowski, A. 
Siomek, M. Foksinski, P. Svoboda, H. Kasai, J.C. Konje, G. Sallsten, M.D. Evans, R. 
Olinski, Interlaboratory comparison of methodologies for the measurement of urinary 8-
oxo-7,8-dihydro-2’-deoxyguanosine, Biomarkers, 14 (2009) 103–10. 
[19] L.W. Garratt, V. Mistry, R. Singh, J.K. Sandhu, B. Sheil, M.S. Cooke, P.D. Sly, 
Arestcf, Interpretation of urinary 8-oxo-7,8-dihydro-2 ’-deoxyguanosine is adversely 
affected by methodological inaccuracies when using a commercial ELISA, Free Radic Biol 
Med, 48 (2010) 1460–1464. 
[20] M.D. Evans, R. Olinski, S. Loft, M.S. Cooke, Toward consensus in the analysis of 
urinary 8-oxo-7,8-dihydro-2’-deoxyguanosine as a noninvasive biomarker of oxidative 
stress, FASEB J, 24 (2010) 1249–60. 
30 
[21] M.S. Cooke, R. Rozalski, R. Dove, D. Gackowski, A. Siomek, M.D. Evans, R. Olinski, 
Evidence for attenuated cellular 8-oxo-7,8-dihydro-2’-deoxyguanosine removal in cancer 
patients, Biol Chem, 387 (2006) 393–400. 
[22] H. Mitsumoto, R.M. Santella, X. Liu, M. Bogdanov, J. Zipprich, H.C. Wu, J. Mahata, 
M. Kilty, K. Bednarz, D. Bell, P.H. Gordon, M. Hornig, M. Mehrazin, A. Naini, M. Flint Beal, 
P. Factor-Litvak, Oxidative stress biomarkers in sporadic ALS, Amyotroph Lateral Scler, 9 
(2008) 177–83. 
[23] S. Toyokuni, T. Tanaka, Y. Hattori, Y. Nishiyama, A. Yoshida, K. Uchida, H. Hiai, H. 
Ochi, T. Osawa, Quantitative immunohistochemical determination of 8-hydroxy-2’-
deoxyguanosine by a monoclonal antibody N451: its application to ferric nitrilotriacetate-
induced renal carcinogenesis model, Lab Invest, 76 (1997) 365–74. 
[24] S. Bouatra, F. Aziat, R. Mandal, A.C. Guo, M.R. Wilson, C. Knox, T.C. Bjorndahl, R. 
Krishnamurthy, F. Saleem, P. Liu, Z.T. Dame, J. Poelzer, J. Huynh, F.S. Yallou, N. 
Psychogios, E. Dong, R. Bogumil, C. Roehring, D.S. Wishart, The human urine 
metabolome, PloS One, 8 (2013) e73076. 
[25] J. Takaki, Associations of job stress indicators with oxidative biomarkers in Japanese 
men and women, Int. J. Environ. Res. Public. Health, 10 (2013) 6662–6671. 
[26] K. Kaneko, T. Kimata, S. Tsuji, A. Ohashi, Y. Imai, H. Sudo, N. Kitamura, 
Measurement of urinary 8-oxo-7,8-dihydro-2-deoxyguanosine in a novel point-of-care 
testing device to assess oxidative stress in children, Clin. Chim. Acta Int. J. Clin. Chem., 
413 (2012) 1822–1826. 
[27] X. Meng, X. Suo, W. Ding, X. Li, Y. Ding, Determination of 8-hydroxy-2’- 
deoxyguanosine derivatized with 4-chloro-7- nitrobenzofurazan in urine by CE-LIF, 
Electrophoresis, 35 (2014) 1873–1879. 
